Goldman Sachs: Hengrui Pharma’s innovative drug growth rebounds; timing of licensing revenue recognition affects profits across two years
Newly reimbursed products are entering hospitals faster, and management maintains its full-year innovative drug sales target; Goldman Sachs raises its earnings forecasts and includes recognition of the Novo Nordisk deal’s upfront payment in the first quarter of 2027.